高强度聚焦超声暴露后钆特醇与钆贝葡胺制剂的稳定性测试
本研究在体外测试了钆特醇和钆贝葡胺两种MR对比剂在临床常用功率高强度聚焦超声(HIFU)暴露后的稳定性。采用高效液相色谱分析暴露前后溶液中钆络合物、游离钆和游离配体的浓度。结果表明,在探索的条件范围内,HIFU暴露未引起两种对比剂的显著解离,也未检测到游离物种浓度的明显增加。
要点
- HIFU暴露后钆特醇和钆贝葡胺的钆络合物浓度与未暴露对照无显著差异。
- 游离钆和/或游离配体偶尔检出,浓度在0.002/0.004% w/w量级,与HIFU强度及持续时间无显著相关。
- 钆贝葡胺的副产物(0.24-0.26%)和游离BOPTA水平(0.07%)与对照样品在实验误差内相当。
诊断标准与关键数值
- 钆特醇制剂处理后络合物浓度与对照无显著差异。
- 游离钆和/或游离配体浓度偶尔为0.002/0.004% w/w量级,与HIFU暴露强度及持续时间无显著相关。
- 钆贝葡胺制剂处理后副产物含量0.24-0.26%,游离BOPTA水平0.07%,与对照样品在实验误差内相当。
临床应用与阅片要点
- 支持钆特醇和钆贝葡胺在HIFU治疗(如子宫肌瘤热消融)期间稳定性良好的假设,为HIFU引导的增强MRI应用提供体外依据。
- 本结果为体外实验,临床应用中仍需结合具体HIFU参数和体内环境综合评估对比剂稳定性。
局限性
- 研究为体外实验,未涉及体内环境对对比剂稳定性的影响。
- 未报告样本量、重复次数及具体HIFU功率参数,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Contrast-enhanced MRI could be useful to guide high-intensity focused ultrasound treatment (HIFU), but the effects of HIFU on gadolinium-based agents is not known. Here, we tested in vitro the stability of gadoteridol and gadobenate dimeglumine, two widely used MR contrast agents, after exposure to HIFU at power levels typically applied in the clinical practice.
METHODS: 0.5 M (gadoteridol and gadobenate dimeglumine) and diluted formulations (1:10 gadoteridol in saline) were exposed to different HIFU sequences. Unexposed and exposed solutions were characterized by high-performance liquid chromatography in terms of concentration of gadolinium complex, free gadolinium and free ligand.
RESULTS: Gadoteridol formulation after treatment showed concentrations of the complex not significantly different from control. Free Gd and/or free ligand concentrations in the order of 0.002/0.004% w/w, were observed occasionally without significant correlation with intensity and duration of exposure to HIFU. Gadobenate dimeglumine formulation after treatment showed complex assay content values, by-products (0.24-0.26%) and free BOPTA levels (0.07%) comparable to control sample within the experimental error.
CONCLUSION: In the range of conditions explored, HIFU exposure did not induce significant dissociations of gadoteridol and gadobenate dimeglumine, nor a detectable increase in the concentration of free species.
ADVANCES IN KNOWLEDGE: Our study strengthens the hypothesis that gadolinium-based contrast agents are stable during HIFU treatment for body applications (e.g. thermal ablation of uterine fibroids).
引用
- Colombo Serra, Gaud, Bano, et al. Stability testing of gadoteridol and gadobenate dimeglumine formulations under exposure to high-intensity focused ultrasound. Br J Radiol. 2022. PMID: 36169642. doi:10.1259/bjr.20220619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。